Search

Displaying results 1901 - 1910 of 4236 in total
  1. Drug

    Oleic Acid

    go.drugbank.com/drugs/DB04224
    ApprovedInvestigationalVet approved

    It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed)

  2. Drug

    Nabumetone

    go.drugbank.com/drugs/DB00461
    Approved

    Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID). … [label,A178903] The molecule itself is a pro-drug with its 6-methoxy-2-naphthylacetic acid (6-MNA) metabolite acting as a potent COX inhibitor similar in structure to [naproxen].

  3. Drug

    Chlorcyclizine

    go.drugbank.com/drugs/DB08936
    Approved

    Chlorcyclizine also has some local anesthetic, anticholinergic, and antiserotonergic properties, and can be used as an antiemetic.

  4. Drug

    Sucrose

    go.drugbank.com/drugs/DB02772
    ApprovedInvestigational

    It is obtained commercially from sugarcane, sugar beet (beta vulgaris), and other plants and used extensively as a food and a sweetener.

  5. Drug

    Istradefylline

    go.drugbank.com/drugs/DB11757
    ApprovedInvestigational

    Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. … [A184067] Istradefylline is indicated as an adjunct treatment to [levodopa] and [carbidopa] for Parkinson's disease.[L8237] This drug was first approved in Japan on 25 March 2013.

  6. Drug

    Taurolidine

    go.drugbank.com/drugs/DB12473
    ApprovedInvestigational

    It was first synthesized in the 1970s and was originally used as a prophylactic against intraperitoneal bacterial infections in patients with peritonitis. … [A263217] In November 2023, a catheter lock solution of taurolidine in combination with [heparin] - marketed as Defencath - received FDA approval under the Limited Population Pathway for Antibacterial

  7. Drug

    Olaratumab

    go.drugbank.com/drugs/DB06043
    ApprovedInvestigational

    Olaratumab was granted accelerated approval (as Lartruvo) as initial therapy to treat adults with certain types of soft tissue sarcoma (STS) in October, 2016.

  8. Drug

    iCo-007

    go.drugbank.com/drugs/DB05268
    Investigational

    ) such as age-related macular degeneration (AMD) and diabetic retinopathy(DR). … iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis

  9. Drug

    Clobutinol

    go.drugbank.com/drugs/DB09004
    ApprovedWithdrawn

    Clobutinol is a cough suppressant that is withdrawn from the US and EU markets. Clobutinol may prolong the QT interval. In 2007, Clobutinol was determined to cause cardiac arrhythmia in some patients.

  10. Drug

    Saquinavir

    go.drugbank.com/drugs/DB01232
    ApprovedInvestigational

    In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared